Nicola Heffron
Sales & Marketing chez ALEXION PHARMACEUTICALS, INC.
Fortune : 108 155 $ au 30/04/2024
Profil
Nicola Heffron is a professional with experience in the pharmaceutical industry.
She is currently the Senior VP, Head-Global Marketing & Market Access at Alexion Pharmaceuticals, Inc. Her former positions include Head-Global Marketing at Celgene Corp.
in 2018, Chief Commercial Officer at bluebird bio, Inc. from 2020 to 2021, and Chief Operating Officer at 2seventy Bio, Inc. from 2021 to 2023.
Ms. Heffron holds an MBA from the University of Warwick.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
2SEVENTY BIO, INC.
0,05% | 13/04/2023 | 25 211 ( 0,05% ) | 108 155 $ | 30/04/2024 |
Postes actifs de Nicola Heffron
| Sociétés | Poste | Début |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Sales & Marketing | 01/04/2023 |
Anciens postes connus de Nicola Heffron
| Sociétés | Poste | Fin |
|---|---|---|
| 2SEVENTY BIO, INC. | Directeur des opérations | 10/03/2023 |
| CELGENE | Sales & Marketing | 01/09/2018 |
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | - |
Formation de Nicola Heffron
| University of Warwick | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| 2SEVENTY BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
